EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer

Yves J L Bodar iD, Liselotte M S Boevé, Pim J van Leeuwen, Phillippe C Baars, Jakko A Nieuwenhuijzen, Ernst P van Haarst, Jorg R Oddens, Maarten L Donswijk, Luigi A M J G van Riel iD, Matthijs J Scheltema, Dennie Meijer iD, N Harry Hendrikse and 2 more

BJU International · 2023-12 · 132 (6) · 705-712

DOI: 10.1111/bju.16167 ↗

At a glance

Journal article in BJU International, published online on 2023-09-13. Written by Yves J L Bodar and 13 co-authors. Institution: Department of Urology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Major MEDLINE topics: Prostate, Prostatic Neoplasms. Cited 17 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

To assess whether a diagnostic pathway in which prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted biopsy and to detect clinically significant prostate cancer (csPCa) in biopsy‐naïve men at high‐risk of disease. Patients and Methods A total of 60 men with a prostate‐specific antigen (PSA) level of 20–50 ng/mL underwent 18 F‐PSMA(DCFPyL)‐PET/CT prior to prostate biopsies in this prospective, non‐randomised cohort study. Magnetic resonance imaging (MRI) was not performed. Using a 12‐segment mapping model of the prostate, PSMA‐guided targeted biopsy was performed along with systematic biopsies. The detection rate of PCa and csPCa was assessed for combined systematic and targeted biopsy, and for targeted biopsy only. csPCa was defined as a prostate biopsy with an International Society of Uropathology (ISUP) Grade Group ≥2.

Results

Lesions suspicious for PCa in the prostate gland were observed on all PSMA‐PET/CTs. A total of 27/60 men (45%) already had metastatic disease on staging 18 F‐PSMA(DCFPyL)‐PET/CT. Combined PSMA‐guided targeted and systematic biopsies detected PCa in 56/60 (93.3%) patients, with 52 of them (92.9%) having csPCa. PSMA‐guided targeted biopsy, if performed as a single biopsy modality, identified PCa in 52/60 men (86.7%) and in 27/27 men (100%) men with metastases.

Conclusions

Using the PSMA‐driven single imaging modality pathway in biopsy‐naïve men at high‐risk of PCa, a substantial number of diagnostic MRI scans could be avoided while at the same time obtaining adequate targeting, staging, and detection of csPCa.

Subjects

MeSH terms (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyCohort StudiesProspective StudiesProstate-Specific AntigenBiopsyPositron-Emission TomographyGallium Radioisotopes

Author keywords

PSMAdetectiondiagnosisprostate cancertarget biopsy

Substances

Prostate-Specific AntigenGallium Radioisotopes

Authors and institutions

  • Department of Urology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear medicine, Amsterdam University Medical Centres (VU University), Amsterdam, The Netherlands.
  • Prostate Cancer Network, Amsterdam, The Netherlands.
  • Department of Urology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
  • Department of Urology, Netherlands Cancer Institute (NCI), Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.

ORCID profiles: Yves J L Bodar, Luigi A M J G van Riel, Dennie Meijer

Cite

APA

Bodar, Y. J. L., Boevé, L. M. S., van Leeuwen, P. J., Baars, P. C., Nieuwenhuijzen, J. A., van Haarst, E. P., Oddens, J. R., Donswijk, M. L., van Riel, L. A. M. J. G., Scheltema, M. J., Meijer, D., Hendrikse, N. H., Oprea-Lager, D. E., & Vis, A. N. (2023). Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer. BJU International, 132(6), 705-712. https://doi.org/10.1111/bju.16167

Vancouver

Bodar YJL, Boevé LMS, van Leeuwen PJ, Baars PC, Nieuwenhuijzen JA, van Haarst EP, et al. Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer. BJU International. 2023;132(6):705-712. doi:10.1111/bju.16167

BibTeX
@article{Bodar2023,
  author = {Bodar, Yves J L and Boevé, Liselotte M S and van Leeuwen, Pim J and Baars, Phillippe C and Nieuwenhuijzen, Jakko A and van Haarst, Ernst P and Oddens, Jorg R and Donswijk, Maarten L and van Riel, Luigi A M J G and Scheltema, Matthijs J and Meijer, Dennie and Hendrikse, N Harry and Oprea-Lager, Daniela E and Vis, André N},
  title = {Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer},
  journal = {BJU International},
  year = {2023},
  volume = {132},
  number = {6},
  pages = {705--712},
  doi = {10.1111/bju.16167}
}
Start for free →